Physician profile
Theodore William Pollock
NPI 1609817246
$1,880.04
in general payments reported to CMS, 2019-2025
30 companies · $14.17 in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $791 · 2020: $378 · 2021: $353 · 2022: $248 · 2023: $16.99 · 2024: $78.31 · 2025: $14.17.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $95.30 · Education: $14.17.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $95.30 |
| Education | $14.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $502.24 | 2019-2024 | Opdivo |
| Astrazeneca Pharmaceuticals LP | $203.08 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $138.37 | 2019-2022 | |
| Genentech USA, INC. | $124.21 | 2019-2020 | |
| Pfizer INC. | $120.68 | 2019-2025 | |
| Astellas Pharma US INC | $99.42 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $98.79 | 2019-2020 | |
| Janssen Biotech, INC. | $70.87 | 2019-2021 | |
| Genzyme Corporation | $58.90 | 2019-2021 | |
| Emd Serono, INC. | $49.17 | 2019 | |
| Puma Biotechnology, INC. | $42.41 | 2019-2020 | |
| Ipsen Biopharmaceuticals, INC | $38.41 | 2020-2021 | |
| Lilly USA, LLC | $37.81 | 2019 | |
| Pharmacyclics LLC, An Abbvie Company | $37.09 | 2019-2021 | |
| Amgen INC. | $33.10 | 2019-2020 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $31.90 | 2019 | |
| Gilead Sciences, INC. | $29.55 | 2019 | |
| Array Biopharma INC | $28.24 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.69 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $20.55 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $18.49 | 2019 | |
| Eisai INC. | $16.49 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $14.43 | 2019 | |
| Karyopharm Therapeutics INC. | $14.25 | 2022 | |
| Abbvie INC. | $13.84 | 2019 | |
| Janssen Scientific Affairs, LLC | $13.06 | 2019 |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Theodore Pollock listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.